SARS-CoV-2 transmitters have more than three times higher viral loads than non-transmitters - Practical use of viral load for disease control

R Jajou, Ajg Mutsaers-van Oudheusden, J J Verweij, A Rietveld, J L Murk, R Jajou, Ajg Mutsaers-van Oudheusden, J J Verweij, A Rietveld, J L Murk

Abstract

Background: Quantitative results of SARS-CoV-2 testing reported as viral load copies/mL can provide valuable information, but are rarely used in practice. We analyze whether viral load in the upper respiratory tract is correlated with transmission and disease course and how this information can be used in practice.

Study design: Municipal Health Service (MHS) and clinical patients ≥18 years tested positive for SARS-CoV-2 with RT-PCR between June 1 and September 25, 2020 were included. Transmission was defined as an index having at least one contact tested positive. Test delay was defined as the time between symptom onset and SARS-CoV-2 testing.

Results: 683 patients were included (656 MHS and 27 clinical patients). The viral load was considerably lower among clinical patients compared to MHS patients: median log10 copies/mL 2.51 (IQR -1.52 - 6.46) vs 4.92 (IQR -0.54 - 8.26), p < 0.0001. However, the test delay was higher for clinical patients (median 7 [IQR 2 - 19] vs 3 [IQR 0 - 26] days, p < 0.0001). SARS-CoV-2 transmitters showed much higher viral loads than non-transmitters (log10 copies/mL 5.23 [IQR -0.52 - 8.26] vs 4.65 [IQR -0.72 - 8.00], p < 0.0001), but not for those with a test delay > 7 days. Higher viral loads were significantly correlated with older age and with more (severe) COVID-19 related symptoms.

Conclusion: Indexes that transmitted SARS-CoV-2 had more than three times higher viral loads than non-transmitters. Viral load information can be useful during source and contact tracing to prioritize indexes with highest risk of transmission, taking into account the test delay.

Keywords: COVID-19; SARS-CoV-2; Test delay; Transmission; Viral load.

Conflict of interest statement

All authors declare no competing interests.

Copyright © 2022. Published by Elsevier B.V.

Figures

Fig. 1
Fig. 1
Test delay and associated viral load (log10 copies/mL) for clinical and Municipal Health Service (MHS) patients.
Fig. 2
Fig. 2
Correlation between viral load (log10 copies/mL) and patient characteristics and disease course. MHS: Municipal Health Service. Bold values denote statistical significance at the p < 0.05 level.
Fig. 3
Fig. 3
Viral load (log10 copies/mL) of indexes that transmitted SARS-CoV-2 and indexes that did not among the total study population (A) and the clinical versus Municipal Health Service (MHS) patients (B). Bold values denote statistical significance at the p < 0.05 level.
Fig. 4
Fig. 4
Viral load (log10 copies/mL) of indexes that transmitted SARS-CoV-2 and indexes that did not, presented by test delay categories (0–3 days, 4–7 days, > 7 days). Bold values denote statistical significance at the p < 0.05 level.
Fig. 5
Fig. 5
Viral load (log10 copies/mL) by secondary attack rate and contact category.

References

    1. Meyerowitz E.A., Richterman A., Gandhi R.T., Sax P.E. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann. Intern. Med. 2021;174:69–79. doi: 10.7326/M20-5008.
    1. van Kampen J.J.A., van de Vijver D.A.M.C., Fraaij P.L.A., et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) Nat. Commun. 2021;12:267. doi: 10.1038/s41467-020-20568-4.
    1. Bergmans B.J.M., Reusken C.B.E.M., van Oudheusden A.J.G., et al. Test, trace, isolate: evidence for declining SARS-CoV-2 PCR sensitivity in a clinical cohort. Diagn. Microbiol. Infect. Dis. 2021 doi: 10.1016/j.diagmicrobio.2021.115392.
    1. Walsh K.A., Jordan K., Clyne B., et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J. Infect. 2020;81:357–371. doi: 10.1016/j.jinf.2020.06.06701.
    1. Zheng S., Fan J., Yu F., Feng B., et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020;369:m1443. doi: 10.1136/bmj.m1443.
    1. Pujadas E., Chaudhry F., McBride R., et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir. Med. 2020;8:e70. doi: 10.1016/S2213-2600(20)30354-4.
    1. Westblade L.F., Brar G., Pinheiro L.C., et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell. 2020;38:661–671. doi: 10.1016/j.ccell.2020.09.007.
    1. Jones T.C., Biele G., Mühlemann B., et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science. 2021;373:eabi5273. doi: 10.1126/science.abi5273.
    1. Lee Y.W.L., Rozmanowsk S., Pang M., et al. SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission. Clin. Infect. Dis. 2021:ciab421. doi: 10.1093/cid/ciab421.
    1. Marks M., Millat-Martinez P., Ouchi D., et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect. Dis. 2021;21:629–636. doi: 10.1016/S1473-3099(20)30985-3.
    1. Corman V.M., Olfert L., Marco K., et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25 doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
    1. RIVM. Wekelijkse update epidemiologische situatie van SARS-CoV-2 in Nederland. 2021. Available at: . Accessed March 11, 2021.
    1. ECDC. Risk factors and risk groups. 2021. Available at: . Accessed March 11, 2021.
    1. RIVM. Coronavirus disease COVID-19. 2021. Available at: . Accessed March 11, 2021.
    1. WHO. Coronavirus disease (COVID-19). 2020. Available at: . Accessed March 11, 2021.
    1. Fajnzylber J., Regan J., Coxen K., et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat. Commun. 2020;11:5493. doi: 10.1038/s41467-020-19057-5.
    1. RIVM. Variants of the coronavirus SARS-CoV-2. 2021. Available at: . Accessed August 5, 2021.
    1. Calistri P., Amato A., Puglia I., et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int. J. Infect. Dis. 2021;105:753–755. doi: 10.1016/j.ijid.2021.03.005.
    1. Teyssou E., Delagrèverie H., Visseaux B., Lambert-Niclot S., et al. The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J. Infect. 2021 doi: 10.1016/j.jinf.2021.08.027. S0163-4453(21)00416-3. doi:
    1. Faria N.R., Mellan T.A., Whittaker C., et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372:815–821. doi: 10.1126/science.abh2644.
    1. Cevik M., Tate M., Lloyd O., Maraolo A.E., Schafers J., Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021;2:e13–e22. doi: 10.1016/S2666-5247(20)30172-5.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться